跳至主要内容
临床试验/NCT01872715
NCT01872715已完成4 期

Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea

Galderma R&D1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2013年3月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Galderma R&D
入组人数
24
试验地点
1
主要终点
Rosacea Score on the Visual Analog Scale

研究概览

简要总结

The purpose of this study is to characterize rosacea patients', being treated with Oracea, perception through visual analog scale reporting.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
25 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men and women
  • 25-70 years
  • Diagnosis of papulopustular rosacea
  • Eligible for Oracea treatment

排除标准

  • Allergies to components of investigational product and/or hypersensitivity to tetracyclines
  • Taken systemic therapy directed at improving rosacea, including antibiotics, within 30 days prior to baseline visit
  • Used topical rosacea treatment within 30 days prior to baseline visit
  • Have active ocular rosacea and/or blepharitis/meibomianitis requiring systemic treatment by an opthalmologist
  • Previously failed to have improvement of rosacea with appropriate use of systemic tetracycline family of antibiotics
  • Exposed to intense/excessive ultraviolet (UV) radiation within one week prior to baseline and/or who forsee unprotected and intense/excessive UV exposure during the course of the study
  • Have planned surgical procedures during the course of the study
  • Have used tetracycline antibiotics within 30 days prior to baseline visit or during study
  • At risk in terms of precautions, warnings, and contraindications

研究组 & 干预措施

Oracea

Experimental

Oracea (doxycycline USP, 40mg[30mg immediate release/ 10mg delayed release beads] taken once daily in the morning on an empty stomach, one hour before meals or two hours after.

Oral dose for 12 weeks

干预措施: Oracea (Drug)

结局指标

主要结局

Rosacea Score on the Visual Analog Scale

时间窗: Baseline, Weeks 2, 6, and 12

VAS = visual analog scale, 10 cm scale in which 0 = no rosacea, 10 = worst rosacea imaginable

次要结局

  • Rosacea-Specific Quality of Life Index(Baseline, Weeks 2, 6, and 12)
  • Patient Global Assessment (PGA) of Rosacea Scores(Baseline, Weeks 2, 6, and 12)
  • Patient Satisfaction Question(Week 2, 6, and 12)

研究者

发起方
Galderma R&D
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验